CL2017000391A1 - Nitrógeno tricíclico que contiene compuestos para el tratamiento de una infección por neisseria gonorrhoea - Google Patents

Nitrógeno tricíclico que contiene compuestos para el tratamiento de una infección por neisseria gonorrhoea

Info

Publication number
CL2017000391A1
CL2017000391A1 CL2017000391A CL2017000391A CL2017000391A1 CL 2017000391 A1 CL2017000391 A1 CL 2017000391A1 CL 2017000391 A CL2017000391 A CL 2017000391A CL 2017000391 A CL2017000391 A CL 2017000391A CL 2017000391 A1 CL2017000391 A1 CL 2017000391A1
Authority
CL
Chile
Prior art keywords
treatment
containing compounds
nitrogen containing
neisseria gonorrhoea
tricyclic nitrogen
Prior art date
Application number
CL2017000391A
Other languages
English (en)
Inventor
Katherine Louisa Widdowson
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of CL2017000391A1 publication Critical patent/CL2017000391A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A MÉTODOS DE TRATAMIENTO DE LA INFECCIÓN POR NEISSERIA GONORRHOEAE QUE COMPRENDEN ADMINISTRAR A UN SUJETO EN NECESIDAD DE ELLO NUEVOS COMPUESTOS TRICICLICOS QUE CONTIENEN NITRÓGENO Y LAS CORRESPONDIENTES COMPOSICIONES FARMACÉUTICAS SEGÚN LO DESCRITO EN EL PRESENTE DOCUMENTO.</p>
CL2017000391A 2014-08-22 2017-02-16 Nitrógeno tricíclico que contiene compuestos para el tratamiento de una infección por neisseria gonorrhoea CL2017000391A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462040488P 2014-08-22 2014-08-22

Publications (1)

Publication Number Publication Date
CL2017000391A1 true CL2017000391A1 (es) 2017-08-18

Family

ID=54072911

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000391A CL2017000391A1 (es) 2014-08-22 2017-02-16 Nitrógeno tricíclico que contiene compuestos para el tratamiento de una infección por neisseria gonorrhoea

Country Status (22)

Country Link
US (2) US10702521B2 (es)
EP (2) EP3639824A1 (es)
JP (2) JP6546654B2 (es)
KR (1) KR20170043603A (es)
CN (2) CN110403939A (es)
AR (1) AR101674A1 (es)
AU (1) AU2015304847B2 (es)
BR (1) BR112017003705B1 (es)
CA (1) CA2958800C (es)
CL (1) CL2017000391A1 (es)
CO (1) CO2017001658A2 (es)
CR (1) CR20170069A (es)
DO (1) DOP2017000049A (es)
EA (1) EA031589B1 (es)
ES (1) ES2759303T3 (es)
IL (1) IL250251A0 (es)
MX (1) MX2017002321A (es)
PE (1) PE20170501A1 (es)
PH (1) PH12017500315A1 (es)
SG (1) SG11201700566SA (es)
TW (1) TW201618779A (es)
WO (1) WO2016027249A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2958800C (en) * 2014-08-22 2020-10-27 Glaxosmithkline Intellectual Property Development Limited Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection
DK3468975T3 (da) 2016-06-08 2020-07-13 Acraf Nye antibakterielle forbindelser
US20200077658A1 (en) 2016-12-16 2020-03-12 Basf Se Pesticidal Compounds
US20220184071A1 (en) * 2019-04-03 2022-06-16 Glaxosmithkline Intellectual Property Development Limited Gepotidacin for use in the treatment of bacterial urinary tract infections
BR112021018815A2 (pt) * 2019-04-03 2022-03-03 Glaxosmithkline Ip Dev Ltd Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário
GB201909191D0 (en) * 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
WO2021004910A1 (en) * 2019-07-05 2021-01-14 Glaxosmithkline Intellectual Property Development Limited Combination for the treatment of infections caused by mycoplasma genitalium
CN115151540A (zh) 2019-12-02 2022-10-04 风暴治疗有限公司 作为mettl3抑制剂的多杂环化合物
CA3176961A1 (en) 2020-04-02 2021-10-07 Glaxosmithkline Intellectual Property Development Limited Regimen for treating a neisseria gonorrhoeae infection with gepotidacin
EP4142731A1 (en) * 2020-04-28 2023-03-08 Noorik Biopharmaceuticals AG Treatment of pulmonary complications of coronavirus infections
US12528809B2 (en) 2020-04-29 2026-01-20 Glaxosmithkline Intellectual Property Development Limited Crystalline forms of gepotidacin
CA3210313A1 (en) * 2021-02-05 2022-08-11 Glaxosmithkline Intellectual Property Development Limited Oral solid dose formulations
EP4316463A1 (en) 2022-08-02 2024-02-07 GlaxoSmithKline Intellectual Property Development Limited Novel formulation
JP2025532252A (ja) 2022-09-26 2025-09-29 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 処置方法
CN121537412B (zh) * 2026-01-16 2026-04-03 南京道尔医药研究院有限公司 一种吉泊达星甲磺酸盐的制备方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA931343B (en) 1992-03-06 1993-09-24 Akzo Nv 1,4-dioxino(2,3-b)pyridine derivatives.
DE69423383T2 (de) * 1993-05-13 2000-08-24 American Cyanamid Co., Wayne Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
GB0207450D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
FR2798656B1 (fr) 1999-09-17 2004-12-17 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent
PL364808A1 (en) 2000-07-21 2004-12-13 Ljudmila Petrovna Maljuk Plate for a stand-up meal
NZ523749A (en) 2000-07-26 2005-03-24 Smithkline Beecham P Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
CZ20031194A3 (cs) 2000-09-29 2003-08-13 Glaxo Group Limited Deriváty močoviny
FR2816618B1 (fr) 2000-11-15 2002-12-27 Aventis Pharma Sa Derives heterocyclylalcoyl piperidine, leur preparation et les compositions qui les contiennent
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
EP1345903A1 (en) 2000-12-21 2003-09-24 Ciba SC Holding AG Crystalline forms of cerivastatin sodium
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0118238D0 (en) 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
WO2003048081A2 (en) 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
US7312212B2 (en) 2002-01-29 2007-12-25 Glaxo Group Limited Aminopiperidine derivatives
WO2003064431A2 (en) 2002-01-29 2003-08-07 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
TW200409637A (en) 2002-06-26 2004-06-16 Glaxo Group Ltd Compounds
TW200406413A (en) 2002-06-26 2004-05-01 Glaxo Group Ltd Compounds
GB0217294D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicaments
FR2844270B1 (fr) 2002-09-11 2006-05-19 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur procede et intermediaires de preparation et les compositions qui les contiennent
FR2844268B1 (fr) 2002-09-11 2004-10-22 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leurs procedes et intermediaires de preparation et les compositions qui les contiennent
EP1551829B1 (de) 2002-10-10 2010-04-07 Morphochem Aktiengesellschaft Für Kombinatorische Chemie Neue verbindungen mit antibakterieller aktivität
AU2003291227A1 (en) 2002-11-05 2004-06-07 Smithkline Beecham Corporation Antibacterial agents
ES2340484T3 (es) 2002-11-05 2010-06-04 Glaxo Group Limited Agentes antibacterianos.
AR042486A1 (es) 2002-12-18 2005-06-22 Glaxo Group Ltd Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion .
TW200507841A (en) 2003-03-27 2005-03-01 Glaxo Group Ltd Antibacterial agents
FR2852954B1 (fr) 2003-03-28 2006-07-14 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
DE10316081A1 (de) 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
WO2004104000A1 (ja) 2003-05-23 2004-12-02 Japan Tobacco Inc. トリサイクリック縮合環化合物およびその医薬用途
FR2858619B1 (fr) 2003-08-08 2006-12-22 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
FR2867472B1 (fr) 2004-03-12 2008-07-18 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
JP2008502689A (ja) 2004-06-15 2008-01-31 グラクソ　グループ　リミテッド 抗菌剤
FR2872164B1 (fr) 2004-06-29 2006-11-17 Aventis Pharma Sa Derives de quinoleines-4-substituees, leur procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
EP1773831A1 (en) 2004-07-08 2007-04-18 Glaxo Group Limited Antibacterial agents
EP1773847A2 (en) 2004-07-09 2007-04-18 Glaxo Group Limited Antibacterial agents
JP2008506695A (ja) 2004-07-13 2008-03-06 グラクソ　グループ　リミテッド 抗細菌剤
JP2008507543A (ja) 2004-07-22 2008-03-13 グラクソ　グループ　リミテッド 抗細菌剤
JP2008508359A (ja) 2004-08-02 2008-03-21 グラクソ グループ リミテッド 抗菌剤
JP2008509222A (ja) 2004-08-09 2008-03-27 グラクソ グループ リミテッド 抗菌剤
DE102004041163A1 (de) 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
JP4887297B2 (ja) 2004-09-24 2012-02-29 アクテリオン ファーマシューティカルズ リミテッド 新規二環式抗生物質
DE602005021133D1 (de) 2004-10-05 2010-06-17 Actelion Pharmaceuticals Ltd Neue piperidin-antibiotika
WO2006046552A1 (ja) 2004-10-27 2006-05-04 Toyama Chemical Co., Ltd. 新規な含窒素複素環化合物およびその塩
EP1845995A4 (en) 2005-01-25 2010-03-03 Glaxo Group Ltd ANTIBACTERIAL AGENTS
JP2008528588A (ja) 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
WO2006081264A1 (en) 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
EP1846411A4 (en) 2005-01-25 2010-08-04 Glaxo Group Ltd ANTIBACTERIAL ACTIVE SUBSTANCES
EP1846416A4 (en) 2005-01-25 2009-07-01 Glaxo Group Ltd ANTIBACTERIAL AGENTS
WO2006099884A1 (en) 2005-03-24 2006-09-28 Actelion Percurex Ag Beta-aminoalcohol antibiotics
US7842810B2 (en) 2005-03-31 2010-11-30 Janssen Pharmaceutica, Nv Bicyclic pyrazole compounds as antibacterial agents
TW200716132A (en) 2005-05-03 2007-05-01 Smithkline Beecham Corp Novel chemical compounds
WO2006125974A1 (en) 2005-05-24 2006-11-30 Astrazeneca Ab Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
EP1888574B1 (en) 2005-05-25 2009-09-02 Actelion Pharmaceuticals Ltd. New antibiotic derivatives
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
WO2006137485A1 (ja) 2005-06-24 2006-12-28 Toyama Chemical Co., Ltd. 新規な含窒素複素環化合物およびその塩
WO2007016610A2 (en) 2005-08-02 2007-02-08 Glaxo Group Limited Antibacterial agents
SI1954697T1 (sl) 2005-10-21 2010-05-31 Glaxo Group Ltd Peri kondenzirane triciklične spojine uporabne kot antibakterijska sredstva
EP1959959B1 (en) 2005-12-06 2013-04-10 Merck Sharp & Dohme Corp. Morpholine carboxamide prokineticin receptor antagonists
ATE465163T1 (de) 2005-12-22 2010-05-15 Glaxo Group Ltd Heterocyclische verbindungen, ihre herstellung und ihre verwendung als antibakterielle mittel
WO2007118130A2 (en) 2006-04-06 2007-10-18 Glaxo Group Limited Antibacterial agents
DE602007009205D1 (de) 2006-04-06 2010-10-28 Glaxo Group Ltd Pyrrolochinoxalinonderivate als antibakterielle mittel
GB0608263D0 (en) 2006-04-26 2006-06-07 Glaxo Group Ltd Compounds
EP2029612A1 (en) 2006-06-09 2009-03-04 Glaxo Group Limited Substituted 1-methyl-1h-quinolin-2-ones and 1-methyl-1h-1,5-naphthyridin-2-ones as antibacterials
GB0613208D0 (en) 2006-07-03 2006-08-09 Glaxo Group Ltd Compounds
EP1992628A1 (en) 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
NZ579877A (en) * 2007-04-20 2011-09-30 Glaxo Group Ltd Tricyclic nitrogen containing compounds as antibacterial agents
JP5474941B2 (ja) * 2008-05-23 2014-04-16 グラクソ グループ リミテッド 窒素含有三環式化合物およびその抗菌剤としての使用
EP2352734A1 (en) * 2008-10-17 2011-08-10 Glaxo Group Limited Tricyclic nitrogen compounds used as antibacterials
CA2958800C (en) * 2014-08-22 2020-10-27 Glaxosmithkline Intellectual Property Development Limited Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection

Also Published As

Publication number Publication date
AU2015304847B2 (en) 2018-10-25
CO2017001658A2 (es) 2017-07-19
CA2958800C (en) 2020-10-27
EP3639824A1 (en) 2020-04-22
US20170304301A1 (en) 2017-10-26
PH12017500315A1 (en) 2017-07-10
DOP2017000049A (es) 2017-03-15
TW201618779A (zh) 2016-06-01
US10702521B2 (en) 2020-07-07
EA031589B1 (ru) 2019-01-31
EP3182973B1 (en) 2019-09-18
WO2016027249A1 (en) 2016-02-25
EP3182973A1 (en) 2017-06-28
ES2759303T3 (es) 2020-05-08
PE20170501A1 (es) 2017-04-27
EA201790442A1 (ru) 2017-08-31
JP2017524029A (ja) 2017-08-24
SG11201700566SA (en) 2017-03-30
BR112017003705A2 (pt) 2017-12-05
JP2019189629A (ja) 2019-10-31
CN110403939A (zh) 2019-11-05
CN106659717B (zh) 2019-09-06
MX2017002321A (es) 2017-08-02
US20200330462A1 (en) 2020-10-22
US11229646B2 (en) 2022-01-25
CA2958800A1 (en) 2016-02-25
CN106659717A (zh) 2017-05-10
BR112017003705B1 (pt) 2022-07-12
AU2015304847A1 (en) 2017-02-23
KR20170043603A (ko) 2017-04-21
AR101674A1 (es) 2017-01-04
CR20170069A (es) 2017-04-28
JP6546654B2 (ja) 2019-07-17
IL250251A0 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
DOP2017000049A (es) Compuestos tricíclicos que contienen nitrógeno para el tratamiento de la infección por neisseria gonorrhoeae
SV2017005489A (es) Terapias de combinación para el tratamiento de cánceres
CO2017012268A2 (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b
NI201600115A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b.
CL2016002971A1 (es) Combinación.
MX2017008720A (es) Derivados y metodos para tratamiento de las infecciones por hepatitis b.
MX2016009337A (es) Derivados de azepano y metodos para tratar infecciones por hepatitis b.
CL2015002891A1 (es) Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales.
CL2017000806A1 (es) Compuestos anti-tnf
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
EA201790575A1 (ru) Триазолопиразиноны в качестве ингибиторов pde1
UY35916A (es) Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
MX377534B (es) Compuestos para usarse en el tratamiento de hiperinsulinemia.
DOP2017000098A (es) Compuesto heterocíclico
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
CL2017000715A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo
BR112017008481A2 (pt) composto antimicótico
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
MX364528B (es) Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas.
EA201691108A1 (ru) Хиназолин-thf-амины в качестве ингибиторов pde1
EA201691773A1 (ru) Галогенированные хиназолин-thf-амины в качестве ингибиторов pde1
MX2017005807A (es) Inmunoterapia especifica de multipeptidos t terapeuticos para el tratamiento de metastasis cerebrales.
EA201691335A1 (ru) Гексагидрофуропирролы в качестве ингибиторов pde1
CL2017001407A1 (es) Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson